1 completed, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow etirinotecan pegol: new trials by email Literature Review of etirinotecan pegol trials Research Report on etirinotecan pegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC JK-1201I - Small Cell Lung Cancer (SCLC) | Phase 1 / Phase 2 | Unknown | JenKem Technology Co., Ltd. | 63 | 2021-11-11 | 2022-01-05 |
| A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety NKTR-102 - Advanced Cancer, Metastatic Solid Tumors | Phase 1 | Completed | Nektar Therapeutics | 33 | 2014-02-01 | 2016-12-22 |
JenKem Technology Co., Ltd. (1) · Nektar Therapeutics (1)
China (1) · United States (1)
Ivan Gergel, MD (1) · Xuan Zhao, Ph.D. (1)